HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

BTMD

biote Corp. (NASDAQ)

Healthcare — Medical Care Facilities

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.

None 5 analysts
$2.35
$-0.17 (-6.75%)
Target: $2.99 (27.1%)
Sign in to add BTMD to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$70.75M
P/E Ratio (TTM)4.63
Forward P/E3.49
EPS (TTM)$0.43
Dividend Yield-
Profit Margin8.29%
Revenue Growth-8.30%
ROE-
Debt/Equity-
Recommendation None
Analyst Target$2.99
Analysts5
Indexes NASDAQ

Technical Indicators

RSI (14)40.4
Beta1.66
SMA 20-
SMA 40-
52-Week High$4.75
52-Week Low$1.27
50-Day Avg$2.14
200-Day Avg$2.33
Avg Volume279.2K
Volume44.9K

Performance Analysis

BULLISH

BTMD shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 31% of its 52-week range.
~ RSI at 40.4 is in neutral territory.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
+ P/E of 4.6 suggests the stock may be undervalued.
- Revenue declined 8.3% year-over-year.
~ Wall Street consensus is "none" from 5 analysts.
+ Average analyst target of $2.99 implies 27.1% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:01 UTC

Back to Screener Export Report